Recent findings have demonstrated that CEMIP exhibits pro-fibrotic functions and acts as a therapeutic target of pirfenidone for the treatment of mild-to-moderate idiopathic pulmonary fibrosis (IPF) [34]. Here, CEMIP is linked to idiopathic pulmonary fibrosis.